|
業務類別
|
Biotechnology |
|
業務概覽
|
Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer. |
| 公司地址
| 451 D Street, Suite 501, 5th Floor, Boston, MA, USA, 02210 |
| 電話號碼
| +1 857 209-0050 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.elicio.com |
| 員工數量
| 33 |
| Dr. Christopher Haqq, M.D.,PhD |
Executive Vice President, Head of Research and Development and Chief Medical Officer |
美元 528.10K |
12/03/2026 |
| Mr. Robert Connelly |
Chief Executive Officer, President and Director |
美元 632.70K |
12/03/2026 |
| Dr. Preetam Shah, M.B.A.,PhD |
Chief Strategy Officer, Chief Financial Officer and Treasurer |
美元 350.61K |
12/03/2026 |
| Dr. Peter DeMuth, PhD |
Chief Scientific Officer |
-- |
12/03/2026 |
|
|
| Dr. Julian Adams, PhD |
Chairman of the Board |
12/03/2026 |
| Dr. Robert R. Ruffolo, Jr, Ph.D |
Independent Director |
12/03/2026 |
| Ms. Karen J. Wilson |
Independent Director |
12/03/2026 |
| Dr. Allen R. Nissenson,M.D. |
Independent Director |
12/03/2026 |
| Dr. Jay R. Venkatesan, M.D. |
Director |
12/03/2026 |
| Ms. Carol Gail Ashe |
Independent Director |
12/03/2026 |
| Mr. Robert Connelly |
Chief Executive Officer, President and Director |
12/03/2026 |
| Ms. Yekaterina Chudnovsky, J.D. |
Director |
12/03/2026 |
|
|
|
|
